CDTX - Cidara Therapeutics, Inc.

QQQ $ 463.74 $ 0.15 (0.03 %)

DIA $ 400.12 $ 2.30 (0.58 %)

SPY $ 543.85 $ 1.71 (0.32 %)

TLT $ 97.88 $ 0.61 (0.63 %)

GLD $ 226.19 $ -1.86 (-0.82 %)

Previous Close

$ 12.86

Open

$ 12.37

Bid

$ 12.66 x 100

Ask

-- x --

Day's Range

$ 12.30 - $ 12.94

52 Week Range

$ 10.00 - $ 24.40

Volume

44,350

Average Volume

Market Cap

58.69M

Beta (5Y Monthly)

$ 1.17

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-15-2024	03-31-2024	10-Q
3	04-22-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-11-2023	03-31-2023	10-Q
7	03-23-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-11-2022	03-31-2022	10-Q
11	03-07-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-12-2021	06-30-2021	10-Q
14	05-13-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-13-2020	06-30-2020	10-Q
18	05-13-2020	03-31-2020	10-Q
19	03-04-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-08-2018	09-30-2018	10-Q
25	08-09-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	02-27-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q
30	05-10-2017	03-31-2017	10-Q
31	03-15-2017	12-31-2016	10-K
32	11-10-2016	09-30-2016	10-Q
33	08-11-2016	06-30-2016	10-Q
34	05-12-2016	03-31-2016	10-Q
35	03-18-2016	12-31-2015	10-K
36	11-16-2015	09-30-2015	10-Q
37	08-11-2015	06-30-2015	10-Q
38	05-21-2015	03-31-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Upgrades Cidara Therap...
08/14/2024 18:45:55

HC Wainwright & Co. analyst Ed Arce upgrades Cidara Therapeutics (NASDAQ:CDTX) from Neutral to Buy and announces $24 pri...

Cantor Fitzgerald Reiterates Overweight on...
08/14/2024 13:37:05

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.

Needham Reiterates Buy on Cidara Therapeut...
08/14/2024 09:41:17

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.

Cidara Therapeutics Q2 2024 Revenue $302K ...
08/13/2024 20:58:37

Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:30:53

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.

Needham Reiterates Buy on Cidara Therapeut...
05/16/2024 11:05:42

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.

Cidara Therapeutics Q1 2024 GAAP EPS $(2.2...
05/15/2024 20:22:08

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of...

Cidara Therapeutics Regains Compliance Wit...
05/15/2024 20:02:29

WBB Securities Maintains Strong Buy on Cid...
04/25/2024 19:30:34

WBB Securities analyst Stephen Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy, adjusts target to $40 (rev...

Needham Maintains Buy on Cidara Therapeuti...
04/25/2024 18:23:28

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy, adjusts target to $25 from $3.

Why Caterpillar Shares Are Trading Lower B...
04/25/2024 17:57:17

Cantor Fitzgerald Reiterates Overweight on...
04/25/2024 14:32:57

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.

Market-Moving News for April 25th
04/25/2024 12:31:16

ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% ...

why-teradyne-shares-are-trading-higher-by-over-8-here-are-20-stocks-moving-premarket

Why Teradyne Shares Are Trading Higher By ...
04/25/2024 10:12:22

Cidara Therapeutics Reacquires Global Deve...
04/24/2024 20:47:52

- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sci...

Cidara Therapeutics Announces Divestiture ...
04/24/2024 20:46:09

Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million ...

Trading Halt: Halt status updated at 8:55:...
04/24/2024 12:55:05

Trading Halt: Halted at 7:50:00 p.m. ET - ...
04/23/2024 23:50:04

why-nucor-shares-are-trading-lower-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Nucor Shares Are Trading Lower? Here A...
04/23/2024 17:53:09

Cantor Fitzgerald Reiterates Overweight on...
04/23/2024 12:54:06

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.